Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate-sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT04409288
What this trial is testing

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Chinese University of Hong Kong 74
Testing effectiveness (Phase 2)Looking for participantsNCT06654336
What this trial is testing

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Who this might be right for
Prostate AdenocarcinomaCastration Sensitive Prostate Cancer
Ontario Clinical Oncology Group (OCOG) 162
Testing effectiveness (Phase 2)Ended earlyNCT00058214
What this trial is testing

Perifosine in Treating Patients With Recurrent Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IIB Prostate Cancer+2 more
National Cancer Institute (NCI) 25
Large-scale testing (Phase 3)Looking for participantsNCT06350825
What this trial is testing

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Who this might be right for
Metastatic Prostate CancerTherapy, Directly Observed
The First Affiliated Hospital with Nanjing Medical University 200
Early research (Phase 1)Active Not RecruitingNCT06193993
What this trial is testing

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic CancerHormone Sensitive Prostate Cancer+1 more
National University Hospital, Singapore 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07649421
What this trial is testing

PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
West China Hospital 254
Large-scale testing (Phase 3)Study completedNCT04191096
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 1,251
Not applicableUnknownNCT05530395
What this trial is testing

BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Who this might be right for
Prostate Cancer Metastatic
Ignacio Puche Sanz 300
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableLooking for participantsNCT07451002
What this trial is testing

Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Cilag S.A.S. 540
Large-scale testing (Phase 3)Looking for participantsNCT07260435
What this trial is testing

Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Nick Beije 400
Large-scale testing (Phase 3)Active Not RecruitingNCT04115007
What this trial is testing

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

Who this might be right for
Oligometastatic Hormone Sensitive Prostate Cancer
UNICANCER 550
Not applicableActive Not RecruitingNCT06874114
What this trial is testing

An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 700
Not applicableLooking for participantsNCT06429813
What this trial is testing

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Who this might be right for
Castrate Sensitive Prostate CancerMetastatic Prostate Cancer
Paul Viscuse 24
Not applicableLooking for participantsNCT06334120
What this trial is testing

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Who this might be right for
Non-metastatic Castration-resistant Prostate CancerMetastatic Hormone-sensitive Prostate Cancer
Bayer 600
Testing effectiveness (Phase 2)Study completedNCT04332744
What this trial is testing

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

Who this might be right for
Metastatic Prostate Cancer
MedSIR 54
Not applicableNot Yet RecruitingNCT07779590
What this trial is testing

Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Pfizer 4,700
Not applicableStudy completedNCT01366053
What this trial is testing

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Who this might be right for
Prostate Cancer
CMX Research 125
Not applicableNot Yet RecruitingNCT07806591
What this trial is testing

Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Bayer 50
Testing effectiveness (Phase 2)Study completedNCT02020070
What this trial is testing

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center 16
Next Page